Acetaminophen overuse in the Ohio Medicaid population

Journal of the American Pharmacists Association

Volumn 43, Issue 6, 2003, Pages 680-684

  Heaton, Pamela C ^a   Cluxton Jr , Robert J ^a   Moomaw, Charles J ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

Acetaminophen; Adverse effects; Database research; Hepatotoxicity; Liver failure; Medicaid utilization; Retrospective studies

Indexed keywords

ANALGESIC AGENT; PARACETAMOL;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; DRUG COMBINATION; DRUG CONTRAINDICATION; DRUG UTILIZATION; FEMALE; HUMAN; LIVER DISEASE; MALE; MEDICAID; MIDDLE AGED; RETROSPECTIVE STUDY; SEX DIFFERENCE; UNITED STATES;

ACETAMINOPHEN; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, NON-NARCOTIC; CROSS-SECTIONAL STUDIES; DRUG COMBINATIONS; DRUG UTILIZATION; FEMALE; HUMANS; LIVER DISEASES; MALE; MEDICAID; MIDDLE AGED; OHIO; RETROSPECTIVE STUDIES; SEX FACTORS;

EID: 1342332199     PISSN: 15443191     EISSN: 15443450     Source Type: Journal    
DOI: 10.1331/154434503322642606     Document Type: Article

References (25)

1. Fast Stats A to Z. Therapeutic Drug Use. 1999. National Center for Health Statistics Web site. Avalable at: www.cdc.gov/nchs/fastats/drugs.htm. Accessed October 1, 2003.
2. Parivash N, Ahmad SR, Karwoski CB. Safety analysis of acetaminophen (APAP)-associated hepatotoxicity. Presented at: Nonprescription Drugs Advisory Committee meeting; Bethesda, Md. September 19, 2002. Available at: www.fda.gov/ohrms/dockets/ac/02/slides/3882S1-05-Nourjah-Ahmad-Karwoski.pdf. Accessed October 1, 2003.
3. Ostapowicz G, Fontana RJ, Schiodt FV, et al. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 2002;137:947-54.
4. Kwan D, Bartle WR, Walker SE. Abnormal serum transaminases following therapeutic doses of acetaminophen in the absence of known risk factors. Dig Dis Sci. 1995;40:1951-5.
5. Barker JD, DeCarle DJ, Anuras S. Chronic excessive acetaminophen use and liver damage. Ann Intern Med. 1977;87:299-301.
6. Leist MH, Gluskin LE, Payne JA. Enhanced toxicity of acetaminophen in alcoholics: report of three cases. J Clin Gastroenterol. 1986;7:55-9.
7. McClain CJ, Kromhout JP, Peterson FJ, Holtzman JL. Potentiation of acetaminophen hepatotoxicity by alcohol. JAMA. 1980;244:251-3.
8. McClain CJ, Holtzman J, Allen J, et al. Clinical features of acetaminophen toxicity. J Clin Gastroenterol. 1988;10:76-80.
9. Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA. 1994;272;1845-50.
10. Fored CM, Ejerblad E, Linbblad P, Fryzek JP. Acetaminophen, aspirin and chronic renal failure. N Engl J Med. 2001;345:1801-8.
11. Acetaminophen safety. Med Lett Drugs Ther. October 28, 2002:91.
12. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, aspirin, and nonsteroidal anti-inflammatory drugs. N Engl J Med. 1994;331:1675-9.
13. Drug Facts and Comparisons. St. Louis, Mo: Facts and Comparisons; 2001:827.
14. Davies DM, Ferner RE, de Glanville H, eds. Textbook of Adverse Drug Reactions. 5th ed. New York, NY: Chapman & Hall Medical; 1998:282.
15. Ohio Medicaid Report. 3rd edition. Columbus, Ohio: Ohio Department of Job and Family Services; 2001. Available at: www.state.oh.us/odjfs/ohp/bhpp/ reports/omr1999/omr1.pdf. Accessed October 1, 2003.
16. International Classification of Diseases, Ninth Revision, Clinical Modification. 4th ed. Los Angeles, Calif: Practice Management Information Corp; 1994.
17. Ruoff GR. Management of pain in patients with multiple health problems: a guide for the practicing physician. Am J Med. 1998;105;53S-60S.
18. Alchol use. In: Summary of Findings from the 2000 National Household Survey on Drug Abuse. Rockville, Md: Substance Abuse and Mental Health Services Administration; 2001. Available at: www.samhsa.gov/oas/NHSDA/2KNHSDA/ Chapter3htm. Accessed October 7, 2003.
19. Aronson MD. Nonsteroidal anti-inflammatory drugs, traditional opioids, and tramadol: contrasting therapies for the treatment of chronic pain. Clin Ther. 1997;19:420-32.
20. Quallich LG, Brown W, Shehab TM, Fontana RJ. Management of acetaminophen hepatotoxicity: a survey of practicing physicians. J Clin Outcomes Manage. 2001;8:25-32.
21. Hawton K, Ware C, Mistry H, et al. Paracetamol self-poisoning: characteristics, prevention and harm reduction. Br J Psychiatry. 1996;168:43-8.
22. Cranney M, Cranney J, Stubbs H. Limitation of over the counter sales of paracetamol: packaging policy is unlikely to achieve its aim of reducing suicide [letter]. BMJ. 1998;317:1657.
23. Ganley J. Issue: unintentional acetaminophen hepatotoxicity. Presented at: Nonprescription Drugs Advisory Committee meeting; Bethesda, Md. September 19, 2002. Available at: www.fda.gov/ohrms/dockets/ac/02/slides/3882s1-01-Ganley. pdf. Accessed: October 7, 2003.
24. Strom BL, Carson JL. Use of automated databases for pharmacoepidemiology research. Epidemiol Rev. 1990;12:87-107.
25. Bright RA, Avorn J, Everitt DE. Medicaid data as a resource for epidemiologic studies: strengths and limitations. J Clin Epidemiol. 1989;42:937-45.